Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 25

RE-LY: Adverse Reactions

As can be seen in the Figure, the most frequent adverse reactions pertaining to dabigatran in the RE-LY trial were GI events, with about a 5% higher incidence of discontinuation due to GI reactions with dabigatran than with warfarin, and with about 20% of subjects experiencing GERD-like symptoms with dabigatran (not shown).[96]

 Reiffel JA. Am J Med 2013; 126: 00-00. 
Complete references for all slides

References

[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

Unable to display view foot.php file not found.